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ed September 10, 2013.he purpose of this study was to determine whether, in patients with ST-segment elevation myocardial infarction
(STEMI) undergoing primary percutaneous coronary intervention (PCI), the reduction in cardiac mortality in those
taking bivalirudin compared with unfractionated heparin plus a glycoprotein IIb/IIIa inhibitor (UFHþGPI) can be fully
attributed to reduced bleeding.Background The association between hemorrhagic complications and mortality may explain the survival beneﬁt with bivalirudin.Methods A total of 3,602 STEMI patients undergoing primary PCI were randomized to bivalirudin versus UFHþGPI. Three-year
cardiac mortality was analyzed in patients with and without major bleeding.Results When compared with UFHþGPI, bivalirudin resulted in lower 3-year rates of major bleeding (6.9% vs. 10.5%, hazard
ratio [HR]: 0.64 [95% conﬁdence interval (CI): 0.51 to 0.80], p < 0.0001) and cardiac mortality (2.9% vs. 5.1%, HR:
0.56 [95% CI: 0.40 to 0.80], p ¼ 0.001). Three-year cardiac mortality was reduced in bivalirudin-treated patients
with major bleeding (20 fewer deaths with bivalirudin; 5.8% vs. 14.6%, p ¼ 0.025) and without major bleeding
(18 fewer deaths with bivalirudin; 2.6% vs. 3.8%, p ¼ 0.048). In a fully-adjusted multivariable model accounting for
major bleeding and other adverse events, bivalirudin was still associated with a 43% reduction in 3-year cardiac
mortality (adjusted HR: 0.57 [95% CI: 0.39 to 0.83], p ¼ 0.003).Conclusions Bivalirudin reduces cardiac mortality in patients with STEMI undergoing primary PCI, an effect that can only partly be
attributed to prevention of bleeding. Further studies are required to identify the nonhematologic beneﬁts of
bivalirudin. (Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial Infarction;
NCT00433966) (J Am Coll Cardiol 2014;63:15–20) ª 2014 by the American College of Cardiology FoundationIn the large-scale, prospective, randomized HORIZONS-
AMI (Harmonizing Outcomes With Revascularization
and Stents in Acute Myocardial Infarction) trial, in patients
with ST-segment elevation myocardial infarction (STEMI)
undergoing primary percutaneous coronary intervention
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013; revised manuscript received September 3,plus a glycoprotein IIb/IIIa inhibitor (GPI) resulted in re-
duced 30-day and 3-year rates of all-cause death, a difference
due to reduced cardiac mortality (1,2). Lower mortality with
bivalirudin compared with UFH alone and UFHþGPI in
patients with STEMI, non-STEMI, and stable coronary
artery disease undergoing PCI has also been reported in
meta-analyses of randomized trials and from large registry
databases (3–6). The mechanism underlying the survival
beneﬁt observed with bivalirudin in these studies, although
not known with certainty, has usually been ascribed to reduced
major bleeding, the rates of which have consistently been 40%
to 50% lower in patients treated with bivalirudin compared
with UFHwith or without GPI (1–11). This belief is based on
the ﬁndings from numerous studies that have reported a strong
relationship between hemorrhagic complications and sub-
sequent mortality, with an associated hazard from bleeding
at least as great as that after myocardial infarction (12–15).
We, therefore, sought to determine the extent to which
the reduction in cardiac mortality after primary PCI
Table 1 Independent Predictors of 3-Year Cardiac Mortality
Risk Factor HR (95% CI) p Value
Abbreviations
and Acronyms
CI = conﬁdence interval
GPI = glycoprotein IIb/IIIa
inhibitor
HR = hazard ratio
PCI = percutaneous coronary
intervention
STEMI = ST-segment
elevation myocardial
infarction
UFH = unfractionated
heparin
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16with bivalirudin compared with
UFHþGPI can be attributed to
reduced bleeding.Age (per 5 yrs) 1.33 (1.21–1.45) <0.001
White blood cell count (per 109 cells/l) 1.12 (1.07–1.18) <0.001
Serum creatinine (per 0.1 mg/dl) 1.11 (1.06–1.16) <0.001
Killip class 2–4 2.28 (1.52–3.42) <0.001
PCI of the left main artery 6.15 (2.26–16.76) <0.001
PCI of the left anterior descending artery 1.65 (1.13–2.42) 0.01
Diabetes, medically-treated 1.58 (1.09–2.29) 0.02
Hemoglobin (per g/dl) 0.89 (0.79–1.00) 0.04
Bivalirudin (vs. UFHþGPI) 0.56 (0.40–0.80) 0.001
Other variables in the model that were not signiﬁcantly associated with cardiac mortality: current
smoker, female sex, prior myocardial infarction, and number of vessels treated.
CI ¼ conﬁdence interval; GPI ¼ glycoprotein IIb/IIIa inhibitor; HR ¼ hazard ratio; PCI ¼ percu-
taneous coronary intervention; UFH [ unfractionated heparin.Methods
Study design. TheHORIZONS-
AMI trial was a prospective,
open-label, randomized, multicen-
ter trial comparing bivalirudin
alone with UFHþGPI (abciximab
or eptiﬁbatide) in 3,602 STEMI
patients presenting within 12 h of
symptom onset and undergoingTable 2
Independent Predictors of 3-Year Cardiac Mortality in
Patients With and Without Major Bleeding at Any Time
Risk Factor HR (95% CI) p Value
Patients with major bleeding
Age (per 5 yrs) 1.32 (1.10–1.57) 0.002
White blood cell count (per 109 cells/l) 1.26 (1.13–1.40) <0.001
Bivalirudin (vs. UFHþGPI) 0.31 (0.13–0.76) 0.005
Patients without major bleeding
Age (per 5 yrs) 1.28 (1.15–1.43) <0.001
Killip class 2–4 2.91 (1.85–4.57) <0.001
PCI of the left main artery 10.56 (3.75–29.77) <0.001
PCI of the left anterior descending artery 1.71 (1.10–2.67) 0.02
Serum creatinine (per 0.1 mg/dl) 1.14 (1.08–1.20) <0.001
White blood cell count (per 109 cells/l) 1.08 (1.02–1.15) 0.008
Diabetes, medically-treated 1.58 (1.03–2.44) 0.04
Hemoglobin (per g/dl) 0.86 (0.75–0.98) 0.04
Bivalirudin (vs. UFHþGPI) 0.65 (0.44–0.97) 0.03
Other variables in the bleeding model that were not signiﬁcantly associated with cardiac mortality:
diabetes, Killip class, PCI of the left anterior descending artery, baseline hemoglobin, serum
creatinine, current smoker, female sex, prior myocardial infarction, and number of vessels treated
(PCI of the left main artery was omitted due to low numbers). Other variables in the non-bleeding
model that were not signiﬁcantly associated with cardiac mortality: current smoker, female sex,
prior myocardial infarction, and number of vessels treated.
Abbreviations as in Table 1.primary PCI (1). A total of 3,006 eligible patients were
randomized again to either paclitaxel-eluting TAXUS Express
(Boston Scientiﬁc, Natick, Massachusetts) stents or otherwise
identical, uncoated bare-metal Express (Boston Scientiﬁc)
stents. Aspirin 324 mg chewed or 500 mg intravenously was
given upfront, and 75 to 81 mg was prescribed daily indeﬁ-
nitely after discharge. A 300- to 600-mg clopidogrel loading
dose was followed with an oral 75-mg dose daily for at least 6
months. Clinical follow-up was performed through 3 years.
Endpoints and deﬁnitions. Cardiac mortality was deﬁned
as death due to myocardial infarction, cardiac perforation or
pericardial tamponade, arrhythmia or conduction abnor-
mality, stroke, procedural complications, or any death in
which a cardiac cause could not be excluded. A post-hoc
analysis of the principal etiology of cardiac death was per-
formed by review of original source documents, blinded to the
randomization arm. Noncardiac death was deﬁned as a death
not due to cardiac causes, including bleeding-related death.
Non-coronary artery bypass graft major bleeding was deﬁned
as intracranial or intraocular hemorrhage, access site bleeding
with 5 cm diameter hematoma or requiring intervention,
hemoglobin decrease 4 g/dl without or 3 g/dl with overt
bleeding, or blood transfusion. In-hospital acquired throm-
bocytopenia was deﬁned as a nadir platelet count <150,000
cells/mm3 in patients without baseline thrombocytopenia. An
independent clinical events committee blinded to treatment
assignment adjudicated all ischemic and bleeding events
using original source documents.
Statistical methodology. Categorical variables were
compared by chi-square or Fisher’s exact test. Independent
predictors of 3-year cardiac mortality were determined
using Cox proportional hazards regression (Table 1).
Treatment effects among patients with and without major
bleeding were then modeled (Table 2). To investigate the
effect of bivalirudin after accounting for adverse events that
bivalirudin is known to reduce (including thrombocyto-
penia and reinfarction, as well as major bleeding), each
event was entered into a time-updated covariate-adjusted
Cox model (Table 3). Analyses were performed using
STATA version 12.1 (StataCorp LP, College Station,
Texas). All signiﬁcance levels are 2-sided, and signiﬁcance
was set at a ¼ 0.05.Results
Outcomes according to pharmacologic randomization.
Baseline characteristics were well matched between patients
allocated to bivalirudin and UFHþGPI (1,2). Treatment
with bivalirudin compared with UFHþGPI resulted in lower
3-year rates of all-cause mortality (5.9% vs. 7.7%, hazard ratio
[HR]: 0.75 [95% conﬁdence interval (CI): 0.58 to 0.97], p ¼
0.03) and cardiac mortality (2.9% vs. 5.1%, HR: 0.56 [95%
CI: 0.40 to 0.80], p ¼ 0.001), with similar rates of noncardiac
mortality (3.1% vs. 2.8%, p ¼ 0.62). After adjusting for
baseline characteristics, treatment with bivalirudin was asso-
ciated with a 44% reduction in cardiac mortality (Table 1).
Bivalirudin also resulted in lower 3-year rates of major
bleeding (6.9% vs. 10.5%, HR: 0.64 [95% CI: 0.51 to 0.80],
p ¼ 0.0001) and reinfarction (6.2% vs. 8.2%, HR: 0.76 [95%
CI: 0.59 to 0.99], p ¼ 0.04), with nonsigniﬁcant differences
in stroke (1.7% vs. 2.0%, p ¼ 0.50), stent thrombosis (4.5%
Table 3
Covariate-Adjusted Independent Predictors of
3-Year Cardiac Mortality*
Risk Factor HR (95% CI) p Value
Age (per 5 yrs) 1.33 (1.21–1.46) <0.001
White blood cell count (per 109 cells/l) 1.14 (1.08–1.20) <0.001
Serum creatinine (per 0.1 mg/dl) 1.08 (1.03–1.14) 0.003
Killip class 2–4 1.63 (1.04–2.56) 0.03
PCI of the left main artery 6.47 (2.30–18.20) <0.001
PCI of the left anterior descending artery 1.62 (1.08–2.43) 0.02
Diabetes, medically-treated 1.51 (1.01–2.25) 0.05
Major bleed 2.53 (1.61–3.98) <0.001
Acquired thrombocytopenia 2.29 (1.49–3.52) <0.001
Reinfarction 7.88 (4.62–13.42) <0.001
Bivalirudin (vs. UFHþGPI) 0.57 (0.39–0.83) 0.003
Other variables in the model that were not signiﬁcantly associated with cardiac mortality: current
smoker, female sex, prior myocardial infarction, number of vessels treated, and baseline hemo-
globin. Model excludes 145 patients with thrombocytopenia at baseline. *Major bleed and rein-
farction are ﬁtted as time-updated covariates from the moment they occurred.
Abbreviations as in Table 1.
Figure 1
Impact of Major Bleeding and Pharmacologic
Randomization on 3-Year Cardiac Mortality
(A) Cardiac mortality in 3,602 enrolled patients with versus without major bleeding
during the 3-year follow-up period. (B) Cardiac mortality in patients randomized to
bivalirudin versus unfractionated heparin (UFH) plus a glycoprotein IIb/IIIa inhibitor
(GPI) with major bleeding. (C) Cardiac mortality in patients randomized to
bivalirudin versus UFHþGPI without major bleeding. CI ¼ conﬁdence interval;
HR ¼ hazard ratio.
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17vs. 5.1%, p ¼ 0.49), and ischemia-driven TVR (14.2% vs.
12.1%, p ¼ 0.06).
Cardiac mortality in patients with and without major
bleeding. Major bleeding occurred in 258 patients (7.2%)
within 30 days and in 306 patients (8.5%) during the 3-year
follow-up period. Cardiac mortality occurred in 84 patients
(2.3%) within 30 days and in 138 patients (3.8%) within 3
years. Three-year cardiac mortality was substantially higher in
patients with versus without a major bleed at any time during
follow-up (Fig. 1). Major bleeding was associated with higher
3-year mortality both in patients treated with UFHþGPI
(14.6%vs. 3.8%,HR: 5.67 [95%CI: 3.59 to 8.96], p< 0.0001)
and bivalirudin (5.8% vs. 2.6%, HR: 4.62 [95% CI: 2.04 to
10.45], p¼ 0.002).Bivalirudin resulted in lowermortality both
in patients with and without major bleeding (Fig. 1). Three-
year cardiac mortality occurred in 38 fewer patients treated
with bivalirudin than UFHþGPI: 20 fewer cardiac deaths
occurred among patients with major bleeding (27 of 185
[14.6%] onUFHþGPI vs. 7 of 121 [5.8%] on bivalirudin, p¼
0.02) and 18 fewer cardiac deaths occurred among patients
withoutmajor bleeding (61 of 1,617 [3.8%] onUFHþGPI vs.
43 of 1,679 [2.6%] on bivalirudin, p ¼ 0.048). After multi-
variable adjustment for baseline differences, bivalirudin
remained associated with reduced mortality both in patients
with and without major bleeding (Table 2).
Infarct size, left ventricular function, and causes of
cardiac death. Among patients randomized to bivalirudin
versus UFHþGPI, there were no differences in median
peak creatine phosphokinase (1,470 [628 to 2,795] ng/ml
vs. 1,436 [604 to 2,671] ng/ml, respectively, p ¼ 0.58) or
creatine phosphokinase-MB (192 [88 to 355] ng/ml vs.
191 [82 to 364] ng/ml, respectively, p ¼ 0.86). Similarly,
among stented patients undergoing protocol-directed
routine 13-month follow-up angiography, there was no
signiﬁcant difference in core laboratory-assessed median
left ventricular ejection fraction with bivalirudin (63.8%
[55.5% to 71.5%], n ¼ 413) vs. UFHþGPI (63.2% [54.3%to 70.3%], n ¼ 381) (p ¼ 0.36). Cardiac death was most
commonly attributed to left ventricular failure or sudden
cardiac death (Online Table 1). The etiology of cardiac
death was similar with bivalirudin versus UFHþGPI in all
patients and the cohorts with and without major bleeding
(Online Table 2).
Severity of bleeding and role of blood transfusions. The
mean decrease in hemoglobin from admission to nadir in
UFHþGPI and bivalirudin-treated patients was 3.9 1.7 g/dl
vs. 3.7 2.0 g/dl, respectively, in patients withmajor bleeding
Stone et al. JACC Vol. 63, No. 1, 2014
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18(p¼ 0.31) and 1.7 1.4 g/dl vs. 1.5 1.3 g/dl, respectively, in
patients without major bleeding (p¼ 0.0007). In-hospital red
blood cell transfusions were administered to 103 patients
(5.7%) treated with UFHþGPI versus 83 patients (4.6%)
treated with bivalirudin (p ¼ 0.13), with mean 3.8  3.9 U
versus 4.2  4.0 U administered, respectively (p ¼ 0.49).
Three-year cardiac mortality in patients transfused compared
with those with major bleeding without transfusion was 26 of
186 (14.2%) versus 15 of 174 (8.6%), respectively (p ¼ 0.11).
In a fully-adjusted multivariable model, the HR for a major
bleed with vs. without transfusion was 1.24 (95% CI: 0.64 to
2.38, p ¼ 0.52).
Among those without major bleeding, minor bleeding
occurred in 254 of 1,617 (15.7%) UFHþGPI-treated
patients versus 141 of 1,679 (8.4%) bivalirudin-treated
patients (p < 0.0001). Three-year cardiac mortality
occurred in 11 of 254 (4.3%) versus 3 of 141 (2.1%) patients
with minor bleeding treated with UFHþGPI versus biva-
lirudin (p ¼ 0.26). After multivariable adjustment, minor
bleeding was not signiﬁcantly associated with cardiac
mortality (HR: 0.98 [95% CI: 0.52 to 1.85], p ¼ 0.94).
Impact of thrombocytopenia. In-hospital acquired throm-
bocytopenia developed in 404 of 3,457 patients (11.7%), and
was strongly associated with 3-year cardiac mortality (8.1% vs.
3.1%, HR: 2.76 [95% CI: 1.85 to 4.14], p ¼ 0.0003). In-
hospital acquired thrombocytopenia occurred in 13.1%
versus 10.4% of patients treated with UFHþGPI versus
bivalirudin, respectively (p ¼ 0.004). Among patients
treated with UFHþGPI, acquired thrombocytopenia was
strongly associated with 3-year cardiac mortality (12.3% vs.
3.5%, HR: 4.36 [95% CI: 2.73 to 6.95], p < 0.0001). In
contrast, among bivalirudin-treated patients, 3-year cardiac
mortality rates were similar in patients in whom throm-
bocytopenia did and did not develop (2.3% vs. 2.5%, HR:
1.44 [95% CI: 0.50 to 4.12], p ¼ 0.51). The effects of
major bleeding and acquired thrombocytopenia on cardiacFigure 2 Interaction Between Major Bleeding and In-Hospital Acquir
(A) Both treatments combined. (B) Results according to randomization to UFHþGPI versmortality were additive in patients treated with UFHþGPI
but not in those treated with bivalirudin (Fig. 2).
Multivariable model accounting for clinical events. After
accounting for baseline characteristics and the time-adjusted
occurrence of adverse clinical events (major bleeding and
reinfarction through 3 years and in-hospital acquired
thrombocytopenia), treatment with bivalirudin compared
with UFHþGPI was independently associated with a 43%
reduction in 3-year cardiac mortality (Table 3).
Analysis of noncardiac mortality according to major
bleeding. Three-year noncardiac mortality was more
frequent in patients with versus without major bleeding (32 of
306 [10.5%] vs. 66 of 3,296 [2.0%], p< 0.0001). There were
no signiﬁcant differences in noncardiac mortality with
UFHþGPI compared with bivalirudin either in patients with
major bleeding (15 of 185 [8.1%] vs. 17 of 121 [14.0%],
respectively, p¼ 0.10) or without major bleeding (31 of 1,617
[1.9%] vs. 35 of 1,679 [2.1%], respectively, p ¼ 0.73).Discussion
In the HORIZONS-AMI trial, anticoagulation with biva-
lirudin rather than UFHþGPI during primary PCI resulted
in a 44% relative (2.2% absolute) reduction in 3-year cardiac
mortality. The improved survival with bivalirudin in the
present and earlier studies (3–6) has typically been attributed
to prevention of major hemorrhagic complications. In this
regard, the present report conﬁrms prior studies (12–15) by
demonstrating the strong association between major bleeding
and subsequent mortality. However, although bivalirudin
resulted in a 36% relative (3.6% absolute) reduction in major
bleeding, this outcome did not fully account for the survival
beneﬁt of bivalirudin. First, among patients with major
bleeding, a smaller proportion of bivalirudin-treated than
UFHþGPI-treated patients died, an effect not explainable
by less-severe bleeding or fewer blood transfusions. Second,ed Thrombocytopenia on 3-Year Cardiac Mortality
us bivalirudin. Abbreviations as in Figure 1.
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19and more striking, fewer patients treated with bivalirudin
versus UFHþGPI died even if overt bleeding did not occur.
Indeed, 18 (47%) of the 38 fewer cardiac deaths with biva-
lirudin occurred in patients without major bleeding.
While the present study was not designed to determine
the mechanisms underlying bivalirudin’s survival beneﬁt, we
have explored several possibilities. In addition to major
bleeding, in-hospital acquired thrombocytopenia has been
linked to mortality in the present and prior studies (16–18).
In the HORIZONS-AMI trial, thrombocytopenia developed
less frequently with bivalirudin versus UFHþGPI, conﬁrm-
ing previous reports (7,19). Notably, however, cardiac
mortality was increased only in patients in whom thrombo-
cytopenia developed after UFHþGPI; acquired thrombocy-
topenia in bivalirudin-treated patients was not associated
with cardiac mortality. Moreover, the deleterious interaction
between major bleeding and thrombocytopenia was marked
in UFHþGPI-treated patients and was absent in bivalirudin-
treated patients. The mechanisms underlying the develop-
ment of thrombocytopenia with UFHþGPI (17,18,20) may
be different than with bivalirudin, and the prognostic impact
of thrombocytopenia may vary accordingly.
In addition to reducing major bleeding and throm-
bocytopenia, treatment with bivalirudin compared with
UFHþGPI was also associated with reduced 3-year rates of
reinfarction. Reinfarction is an important cause of mortality
after primary PCI (21,22), and this reduction may have
contributed to the survival beneﬁt of bivalirudin. However,
even after accounting for major bleeding, thrombocytopenia,
and reinfarction in a time-adjusted multivariable model,
treatment with bivalirudin remained independently associ-
ated with a 43% reduction in 3-year cardiac mortality,
similar to the 44% reduction observed before these adverse
events were taken into account.
Direct thrombin inhibition may reduce inﬂammation and
apoptosis (23–25), improve post-ischemic myocardial func-
tion (24), and reduce infarct size (23). Thrombin blockade of
protease-activated receptor-1 signaling may reduce cardiac
remodeling and heart failure after STEMI (26), and protease-
activated receptor-4 inhibition may reduce reperfusion injury
(27). Bivalirudin may otherwise ameliorate reperfusion injury
(28,29). UFH but not bivalirudin also increases circu-
lating levels of antiangiogenic peptides, which may impair
myocardial recovery (30). Intramyocardial hemorrhage can
occur after UFHþGPI (31,32), which might be prevented by
bivalirudin. Infarct size was nonsigniﬁcantly smaller with
bivalirudin compared with UFHþGPI in the single-center
HORIZONS-AMI cardiac magnetic resonance imaging
substudy, and microvascular obstruction tended to be less
(33). Consistent with this observation, post-PCI coronary
ﬂow reserve was greater in patients treated with bivalirudin
rather than UFHþGPI in PROTECT–TIMI 30 (A
Randomized Trial to Evaluate the Relative Protection
Against Post-PCI Microvascular Dysfunction and Post-PCI
Ischemia Among Anti-Platelet and Anti-Thrombotic
Agents–Thrombolysis In Myocardial Infarction 30) (34).However, post-PCI myocardial blush (35) and ST-segment
resolution (36) were comparable in bivalirudin- and
UFHþGPI-treated patients, and biomarker-assessed infarct
size and follow-up left ventricular ejection fraction were also
similar. Further studies are required to elucidate the non-
hematologic attributes of bivalirudin that contribute to its
survival beneﬁt.
Study limitations. First, the present observations do not
prove causality, and are hypothesis-generating. Second, to
exclude the dilutional effects of noncardiac mortality (the rates
of which were similar between groups), the present analysis
was restricted to cardiacmortality. In this regard, the reduction
in cardiac mortality with bivalirudin compared with
UFHþGPI was robust (HR: 0.56 [95% CI: 0.40 to 0.80],
p ¼ 0.001), making type I error unlikely, although play of
chance cannot totally be excluded. Third, although aspirin and
thienopyridine usage was similar in the treatment arms
throughout3 years (2), aswas use of beta-blockers, angiotensin-
converting enzyme inhibitors, and statins at discharge (1), we
did not assess nonantiplatelet agent usage beyond discharge.
Finally, although femoral artery access was most common (1),
the demonstration that the survival beneﬁt of bivalirudin was
present in patients without major bleeding suggests bivalirudin
might reduce mortality after radial artery intervention. An
adequately-powered randomized trial of primary PCI with
radial access is required to test this hypothesis.
Conclusions
In the HORIZONS-AMI trial, treatment with bivalirudin
rather than UFHþGPI resulted in a marked reduction in
cardiac mortality after primary PCI, a beneﬁt that was present
by 30 days and increased in magnitude over 3 years (1,2). The
mechanisms through which bivalirudin exerts this survival
beneﬁt are multifactorial, and cannot entirely be explained by
prevention of bleeding. Notably, the impact of major bleeding
occurring after treatment with bivalirudin compared with
UFHþGPI on subsequent cardiac mortality was attenuated,
despite the severity of bleeding being similar in magnitude.
Moreover, bivalirudin was strongly associated with reduced
cardiac mortality even in patients without any bleeding and
even after accounting for all adverse events known tobe reduced
by bivalirudin (bleeding, thrombocytopenia, and reinfarction).
Further studies are required to identify the nonhematologic
beneﬁts of bivalirudin in patients undergoing PCI.
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